GSK offers concessions and starts divestments

25 June 2019 - Deborah Wilkes

Premium

GlaxoSmithKline (GSK) appears to have offered concessions to the European Commission as it seeks approval for its proposed consumer healthcare joint venture with Pfizer. Meanwhile, media reports suggest GSK has started a sale process for three portfolios of consumer healthcare products with a combined price tag of around GBP1 billion (USD1.3 billion).

Click tags below for more information on topics:

GlaxoSmithKline

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: